Non-peptidic glucose-like peptide-1 receptor agonists: Aftermath of a serendipitous discovery

Acta Pharmacologica Sinica

Volumn 31, Issue 9, 2010, Pages 1026-1030

  Wang, Ming Wei ^a   Liu, Qing ^a   Zhou, Cai Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

agonist; G protein coupled receptor; glucagon like peptide 1; type 2 diabetes mellitus

Indexed keywords

AVE 0010; BOC5; CJC 1134 PC; CYCLOBUTANE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; LY 2189265; LY 2428757; S4P; SAXAGLIPTIN; SITAGLIPTIN; T 0632; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

BINDING AFFINITY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; RECEPTORS, GLUCAGON; SMALL MOLECULE LIBRARIES;

EID: 77956358720     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.107     Document Type: Review

References (37)

1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl 1: 1-68.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101
4. Shi Z. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 2425; author reply 2426.
5. Unger J, Parkin CG. Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med 2010; 122: 145-157
6. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009; 49 Suppl 1: S16-29.
7. Chia CW, Egan JM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes 2009; 2: 37.
8. Wysham CH. New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. Postgrad Med 2010; 122: 52-60.
9. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596
10. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
11. van Genugten RE, van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract 2009; 86 Suppl 1: S26-34.
12. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52: 25-27
13. Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, van Vliet AA. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther 2008; 46: 443-452
14. A study of dose titration of LY2189265 in overweight patients with type 2 diabetes meellitus (EGO). http://clinicaltrials.gov/ct2/show/NCT00630825.
15. A study for patients with type 2 diabetes mellitus. http:// clinicaltrials. gov/ct2/show/NCT00804986.
16. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008; 134: 1137-1147
17. Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials. http://www.roche.com/med-cor-2008-06-10-e.pdf.
18. New diabetes compound AVE0010 showed clear dose response results with once -a day injection in phase IIb study. http://en.sanofi-aventis.com/press/ press-releases/2008/ppc-19592.asp
19. New drug application for Galvus®, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA. http://www.glucagon. com/pdfs/VildagliptinUSNDAFilingpress%20release.pdf.
20. FDA approves new drug treatment for type 2 diabetes. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm174780. htm.
21. Sitagliptin and Vildagliptin. http://www.npci.org.uk/therapeutics/cardio/ diabetes2/resources/library-oth-future-medicines- sitagliptin-vildagliptin.pdf
22. Merrion announces license agreement with Novo Nordisk to develop oral formulation of GLP-1 receptor agonist(s). http://www.merrionpharma.com/archive/ Merrion-NN-GLP-1.pdf
23. Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today 2005; 10: 417-427
24. Mjalli AM, Polisetti DR, Yokum TS, Kalpathy S, Guzei M, Behme C, et al. Oxadiazoanthracene compounds for the treatments of diabetes. WO Patent 2009111700. 2009; March 6.
25. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA 2007; 104: 943-948
26. Su H, He M, Li H, Liu Q, Wang J, Wang Y, et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One 2008; 3: e2892.
27. Kopin AS, Beinborn M. Methods and compositions for the treatment of metabolic disorders. WO Patent 2004103310. 2004; May 20.
28. Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 2001; 276: 37787-37793
29. Nishimura T, Nagase T, Eiki J. Novel diallylmethylamine derivative. WO Patent 02067918. 2002; February 27.
30. Teng M, Truesdale LK, Bhumralkar D, Kiel D, Johnson MD, Thomas C, et al. Non-peptide GLP-1 agonists. WO Patent 0042026. 2000; January 14.
31. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al. Small-molecule agonists for the glucagons-like peptide 1 receptor. Proc Natl Acad Sci USA 2007; 104: 937-942
32. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T, et al. Small molecule ago-allosteric modulators of the human glucagonslike peptide-1 (hGLP-1R) receptor. Bioorg Med Chem Lett 2007; 17: 5472-5478
33. Wang MW, Yuan YY, Zhou L, Young AA, Zhang A, Gao LD, et al. A kind of receptor signaling transduction positive modulators, preparation methods and uses thereof. WO Patent 2009129696. 2009; April 27.
34. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008; 283: 11340-11347
35. Lin F, Wang R. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. J Mol Model 2009; 15: 53-65.
36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
37. Murphy KG, Bloom SR. Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes? Proc Natl Acad Sci USA 2007; 104: 689-690